Results for tag: "Shingrix"

Shingrix is a vaccine developed by GlaxoSmithKline (GSK) to protect against shingles, a painful and contagious skin rash caused by the varicella-zoster virus. It is a non-live, recombinant subunit vaccine, which means it is made from a protein that is found on the surface of the virus. It is administered in two doses, with the second dose given two to six months after the first. Shingrix is approved for use in adults aged 50 and over in the United States, Canada, and the European Union. It is recommended for all adults aged 50 and over, regardless of whether they have had shingles before. It is also recommended for adults aged 60 and over who have previously received the Zostavax vaccine. The Shingrix market is a growing one, with GSK leading the way in the development and distribution of the vaccine. Other companies in the market include Merck, Sanofi, Pfizer, and AstraZeneca. These companies are involved in the research, development, and distribution of vaccines for shingles and other diseases. Show Less Read more